LEADER 01207cam0-22004691i-450- 001 990000031970403321 005 20050704122038.0 035 $a000003197 035 $aFED01000003197 035 $a(Aleph)000003197FED01 035 $a000003197 100 $a20020821d1980----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa-------001yy 200 1 $aProgetto realizzato$fCarlo Aymonino ... [et al.] 210 $aVenezia$cMarsilio$d1980 215 $a262 p.$cill.$d21 cm 225 1 $aPolis$v22 225 1 $aPolis$iProgetti$v1 610 0 $aArchitettura 610 0 $aEdilizia Ospedaliera 610 0 $aEdilizia Scolastica 610 0 $aEdilizia Residenziale 610 0 $aArchitettura$aItalia 676 $a720 676 $a727 676 $a728 676 $a725 676 $a720.945 702 1$aAymonino,$bCarlo$f<1926- > 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000031970403321 952 $a13 D 51 11$b32433$fFINBC 952 $a08 A 123$b6978 (AT)$fDINED 952 $a01 FA 3082$b05055$fDINST 959 $aFINBC 959 $aDINED 959 $aDINST 996 $aProgetto realizzato$9105826 997 $aUNINA LEADER 03855 am 22004813u 450 001 9910563180503321 005 20230617021834.0 035 $a(CKB)2670000000334399 035 $a(SSID)ssj0000985785 035 $a(PQKBManifestationID)11543079 035 $a(PQKBTitleCode)TC0000985785 035 $a(PQKBWorkID)10929427 035 $a(PQKB)10285889 035 $a(WaSeSS)Ind00073618 035 $a(EXLCZ)992670000000334399 100 $a20160829d2004 uy | 101 0 $ager 135 $aur||#|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$a"Adieu ihr lieben Schwarzen" $eGesammelte Schriften des Tiroler Afrika-Missionars Franz Mayr (1865-1914) /$fherausgegeben und kommentiertvon Clemens Gütl 210 31$aAustria :$cBo?hlau Verlag,$d2004 215 $a1 online resource (405 pages) $cdigital, PDF file(s) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$aPrint version: 9783205771449 320 $aIncludes bibliographical references. 330 $aFranz Mayr was "one of the most interesting of catholic missionaries in Southern Africa" states Professor Joy Brain ("University of Durban") in the foreword she wrote for this first edition of his writings. Mayr was born in the Austrian province of Tyrol in 1865, educated as a priest in the diocese of Brixen and arrived in Natal (South Africa) at the beginning of May 1890, inspired by the work being done there by the Trappist-Monks led by Abbot Franz Pfanner. Mayr was physically handicapped and soon left the trappists but just to offer his services to the vicar apostolic of Natal, Bishop Charles Jolivet, who accepted him for work among the African population. He was sent to Pietermaritzburg then capital of the British colony to take over the care of the African parishioners to bring the "good news" to those who had never heard it. He founded several new mission-stations in Natal, Southern Rhodesia (present day Zimbabwe) and Swaziland where he was killed by a native robber in 1914. Mayr - a man of many talents - was a gifted linguist, studied and published books in several African languages. He was interested in cultural anthropology and collected information about African customs. It is now more than a hundred years since Franz Mayr began his work of evangelisation and scholarship in Southern Africa. Publishing his letters and articles - kept by several archives in Europe - should help to remember a man of the Habsburg-Monarchy who went to preach the gospel to the so called heathen of Africa. Although Austria or Austria-Hungary never owned colonies in Africa many of its inhabitants left their homes to work in catholic mission-stations around the continent. Several introductory chapters in this book explain the particular historical context which has to be put into consideration when reading Mayrs' writings. From there we learn about his life, his work, how he treated the native population, what he thought about other religious congregations around him, the colonialists and about troubles when trying to convince people to believe in the only - the "European God". The missionary deserves to be better known. The present edition of historical sources is to be seen as a most relevant step allowing us to interpret his personality adequately. 606 $aReligion$2HILCC 606 $aPhilosophy & Religion$2HILCC 606 $aChristianity$2HILCC 607 $aKwaZulu-Natal (South Africa)$xChurch history 615 7$aReligion 615 7$aPhilosophy & Religion 615 7$aChristianity 700 $aMayr$b Franz$f1865-1914.$01223446 702 $aGütl$b Clemens 801 0$bPQKB 801 2$bUkMaJRU 906 $aBOOK 912 $a9910563180503321 996 $a"Adieu ihr lieben Schwarzen"$92838245 997 $aUNINA LEADER 03706nam 2200793z- 450 001 9910557380603321 005 20220111 035 $a(CKB)5400000000042093 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76940 035 $a(oapen)doab76940 035 $a(EXLCZ)995400000000042093 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aSmall Cell Lung Cancer: A New Era Is Beginning? 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (150 p.) 311 08$a3-0365-2301-4 311 08$a3-0365-2302-2 330 $aSmall-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. 517 $aSmall Cell Lung Cancer 606 $aMedicine$2bicssc 610 $aatezolizumab 610 $abiology of SCLC 610 $achemotherapy 610 $acirculating tumor cells 610 $aDDR 610 $adurvalumab 610 $aextensive disease 610 $aextensive-stage small cell lung cancer 610 $agene pathway 610 $aICB 610 $aimmune checkpoint inhibitors 610 $aimmune-checkpoint inhibitors in SCLC 610 $aimmunotherapy 610 $aImmunotherapy 610 $aipilimumab 610 $alobectomy 610 $alurbinectedin 610 $amultimodal treatment 610 $an/a 610 $anivolumab 610 $aPARP 610 $apathobiology 610 $apathology and classification of SCLC 610 $apembrolizumab 610 $apneumonectomy 610 $aprognostic biomarker 610 $aradiotherapy 610 $aSCLC 610 $aSLFN11 610 $asmall cell lung cancer 610 $asmall-cell lung cancer 610 $aSTING 610 $asynthetic lethality 610 $atargeted agents 610 $atargeted therapy 615 7$aMedicine 700 $aMorabito$b Alessandro$4edt$01326702 702 $aRolfo$b Christian$4edt 702 $aMorabito$b Alessandro$4oth 702 $aRolfo$b Christian$4oth 906 $aBOOK 912 $a9910557380603321 996 $aSmall Cell Lung Cancer: A New Era Is Beginning$93037687 997 $aUNINA